Poster presenting preclinical data for the ONCO Prime platform at theAACR Annual Meeting 2026

The Management Board of Ryvu Therapeutics S.A., with its registeredoffice in Kraków (the "Company", "Ryvu"), with reference to currentreport No. 5/2026 and current report No. 5k/2026 dated March 18, 2026,hereby informs that on April 20, 2026, during the AACR Annual Meetingheld on April 17-22, 2026 in San Diego, California, the Companypresented preclinical data for the ONCO Prime platform.

Details on the poster presentation are as follows:

Poster Title: "ONCO Prime platform enables discovery of synthetic lethaltargets for genetically stratified cancers"

Poster: 2989

Session date and time: 20/04/2026, 2:00 PM - 5:00 PM EST

Colorectal cancer (CRC) remains a leading cause of cancer mortality,underscoring the need for new, mechanism-based therapeutic strategies.Using the ONCO Prime discovery and validation platform, based ongenome-wide CRISPR/Cas9 screenings across clinically relevant models, weidentified novel treatment options for genetically stratified CRCpatients.

The ONCO Prime platform integrates healthy human intestinal stem cells(hISCs), isogenic CRC models carrying key driver mutations (APC, KRAS),and patient-derived primary cultures. All types of models can begenetically manipulated or used in the high-throughput setting for drugscreening. Transcriptomic and machine learning analyses confirmed thatthese models faithfully recapitulate CRC molecular diversity andclinical behavior.

Systematic CRISPR/Cas9 loss-of-function screenings revealed multiplesynthetic lethal (SL) interactions, uncovering target genes withfirst-in-class therapeutic potential. Additionally, using aclinical-grade drug that is FDA-approved in other indications, weachieved proof of concept in genetically stratified CRC models,demonstrating strong efficacy as monotherapy in vitro. These datavalidate ONCO Prime's translational capability to uncover clinicallyactionable vulnerabilities and deliver tangible therapeutic candidates.

This work provides a robust foundation for drug discovery programs andstrategic partnerships built on ONCO Prime's ability to bridgefunctional genomics with therapeutic development. Our first proof ofconcept establishes ONCO Prime as a scalable platform to drive the nextgeneration of precision, first-in-class oncology therapies.

Poster is now available online and can be obtained from the conferencesite:

https://www.aacr.org/

Disclaimer: This English language translation has been prepared solelyfor the convenience of English-speaking readers. Despite all the effortsdevoted to this translation, certain discrepancies, omissions orapproximations may exist. In case of any differences between the Polishand the English versions, the Polish version shall prevail. RyvuTherapeutics S.A., its representatives and employees decline allresponsibility in this regard.